Strategies for Continued IRT Success During COVID-19 Date Published: Jun 24, 2020 Article Featured in Journal for Clinical Studies, this article discusses the challenges IRT customers face with the recent COVID-19 pandemic and how to mitigate these potential issues to avoid interrupting ongoing clinical trials. Discover best practices for: Distribution challenges Screening & enrollment challenges A properly configured and adaptive IRT system can enable organizations to remain flexible and agile enough to face any challenge. Signant Health’s team of IRT designers, developers, supply experts, and statisticians are available to consult on challenges and best practices. Download Now Share: LinkedInTweet Recommended Resources Article Optimal COA Measurement Strategy in Modern Oncology Trials The inclusion of patient-reported outcomes (PRO) data in oncology medication labeling in the U.S. has been comparatively limited. Recent FDA... Read Now Article Innovations in Clinical Neuroscience: Articles on Pediatric and Orphan Disease Clinical Research Dr. Joan Busner, Signant’s Clinical Vice President and in-house expert on pediatric and orphan disease clinical trials, recently co-authored three... Download Now Article Cariprazine Found to be Effective Adjunctive Treatment for Major Depressive Disorder Treating major depressive disorder can be challenging since many patients do not respond to initial antidepressant treatment, leading to continued... Read the Article